Parameter
| Biomarker | LGI1 Ab | Full name | Leucine-Rich Glioma-Inactivated 1 Antibody | Molecular Type | Autoantibody |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Etiology |
| Disease | Epilepsy | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Serum/Cerebrospinal Fluid (Indirect Immunofluorescence, ELISA) | ||
| Pathobiological Mechanisms | Targets the neuronal surface LGI1 protein, disrupts the voltage-gated potassium channel complex, and induces limbic encephalitis-related seizures. | ||||
| Clinical Availability Status | Clinically available | ||||
| Notes and Dynamics | Specificity reaches 92%, sensitivity 88%; the response rate of immunoglobulin therapy in antibody-positive patients exceeds 70%. | ||||